A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

What Was Tested

In this phase 1 trial, researchers set out to test Retatrutide and Dulaglutide.

The main purpose of this study is to learn about the side effects of LY3437943 when given to participants with type 2 diabetes.

Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Each enrolled participant will receive injections of LY3437943, dulaglutide, or placebo given just under the skin.

It had three arms (groups): LY3437943 (experimental), Dulaglutide (active comparator) and Placebo (placebo comparator).

LY3437943 administered subcutaneously (SC).

Dulaglutide administered SC.

Placebo administered SC.

The registry classes the interventions as drug.

Who Took Part

The registry lists 72 actual participants took part.

It was open to people of any sex aged from 20 years up to 70 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have T2DM for at least 3 months before screening and are without advanced known possible complications of diabetes mellitus. Have a body mass index of 23 to 50 kilograms per square meter (kg/m²), inclusive.

The full record lists 6 inclusion and 6 exclusion criteria; among the exclusions: have type 1 diabetes mellitus or latent autoimmune diabetes in adults; have uncontrolled diabetes, defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening; have had an episode of severe hypoglycemia.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

The participants were allocated by chance, so the Retatrutide group and the comparison group should start out alike.

The Retatrutide group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the participants and researchers unaware of who received Retatrutide.

Those kept unaware of assignments: participant and investigator.

It started in 2019-12-18 with completion listed for 2020-12-28.

It ran at 4 sites in United States (4).

Its stated primary purpose is basic science.

What Was Measured

Researchers chose this as the main measure: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration (time frame: Baseline through Day 106).

It also tracked 3 secondary outcomes, for example PK: Maximum Concentration (Cmax) of LY3437943 and Change from Baseline in Mean Daily Plasma Glucose (PG).

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Retatrutide and Dulaglutide in 72 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Retatrutide compound page and the Dulaglutide compound page, all human trials.